Read + Share
Kermorgant S. Rationale for Cotargeting Hepatocyte Growth Factor and Epidermal Growth Factor
Receptor in Recurrent/Metastatic Head and Neck Cancer. J Clin Oncol 2023 Jun 15:JCO2300460. doi: 10.1200/JCO.23.00460.
PMID: 37319388
|
 |
|
Kermorgant S. Rationale for Cotargeting Hepatocyte Growth Factor and Epidermal Growth Factor
Receptor in Recurrent/Metastatic Head and Neck Cancer. J Clin Oncol 2023 Jun 15:JCO2300460. doi: 10.1200/JCO.23.00460.
PMID: 37319388
|
|
|
|